Cuál es el precio por Structure Therapeutics Inc. (GPCR)

Precio por Structure Therapeutics Inc. (GPCR) es de$49.68

Cuál es la capitalización de mercado por Structure Therapeutics Inc. (GPCR)

Capitalización de mercado por Structure Therapeutics Inc. (GPCR) es $2.86B

Structure Therapeutics Inc. (GPCR) Historial de Precios

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.

Año	Rendimiento
2026 (TTM)	-18.19%
2025	90.66%
2024	-37.07%
2023	0.00%

Año

Rendimiento

2026 (TTM)

-18.19%

2025

90.66%

2024

-37.07%

2023

0.00%

Empresa	Precio de la acción	Cambio 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$549.38	41.20%	US
Argenx SE ARGX.US	$1.05K	47.75%	NL
Moderna, Inc. MRNA.US	$148.35	491.02%	US
CSL Limited CSL.AX	$122.50	-12.74%	AU
Lonza Group AG LONN.SW	$764.47	7.08%	CH

Empresa

Precio de la acción

Cambio 1a%

País